Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02481947 · ClinicalTrials.gov registry record · Phase 3

A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults

A Phase 3 study, sponsored by Braintree Laboratories.

Completed
Registry status
Phase 3
Development phase
459
Enrollment target

NCT02481947 is a Phase 3 study that has completed, run by Braintree Laboratories. The registered enrollment target is 459 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02481947, a Phase 3 study, has completed, sponsored by Braintree Laboratories.

COMPLETED
Registry status
Phase 3
Development phase
459 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate a daily dose of BLI400 Laxative for safety and efficacy versus lubiprostone in constipated adults.

Interventions

  • DRUG Lubiprostone
  • DRUG BLI400 Laxative

Trial Details

FieldValue
Enrollment Target 459 participants
Start Date 2015-05
Est. Completion 2015-11
Phase Phase 3

Sponsor

Braintree Laboratories

49 total trials

What the Registry Record Tells You About NCT02481947

The ClinicalTrials.gov registry entry for NCT02481947 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 459 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Braintree Laboratories, which has 49 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Lubiprostone is the first listed.

NCT02481947 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02481947 about?

NCT02481947 is a clinical study titled "A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults". The purpose of this study is to evaluate a daily dose of BLI400 Laxative for safety and efficacy versus lubiprostone in constipated adults.

What is the current status of trial NCT02481947?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 459 participants. The study started on 2015-05. Estimated completion is 2015-11.

What interventions are being tested in trial NCT02481947?

The interventions under investigation include: Lubiprostone (DRUG), BLI400 Laxative (DRUG).

Who is sponsoring clinical trial NCT02481947?

This trial is sponsored by Braintree Laboratories, which has 49 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.